Treatment protocols
The studies and protocols your team will mention, worked through in plain words: the pathways, the odds by risk group, what the study found and what it can't tell you about your kid. AALL1731 in full, AALL1732 in progress.
- Active, not recruiting
AALL1731: the study behind your kid's roadmap
If your kid has standard-risk B-cell acute lymphoblastic leukemia (B-ALL), you are going to hear “1731” a lot. It is the study that put blinatumomab, or blina, into standard treatment for children. Not every kid on the protocol gets blina, so I have laid out the different 1731 pathways and the numbers that go with each one. I found these figures hard to track down and understand. I hope having them together helps other parents. There are a lot of statistics here, but every child has their own journey. For a parent, the number that matters most is n=1: one child, your kid. These figures cannot tell you how your kid’s treatment will go, but they can help you understand the possibilities.
- RecruitingPlaceholder, not written yet
AALL1732: the high-risk study
This page is a placeholder. I have not started the real write-up of AALL1732 yet. If your kid has high-risk B-ALL, the roadmap may say “1732”: it is the Children's Oncology Group study asking whether adding inotuzumab ozogamicin to the usual chemotherapy keeps more kids in remission.